These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21707574)

  • 1. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
    Lopez-Girona A; Heintel D; Zhang LH; Mendy D; Gaidarova S; Brady H; Bartlett JB; Schafer PH; Schreder M; Bolomsky A; Hilgarth B; Zojer N; Gisslinger H; Ludwig H; Daniel T; Jäger U; Chopra R
    Br J Haematol; 2011 Aug; 154(3):325-36. PubMed ID: 21707574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Patil A; Manzano M; Gottwein E
    Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma involves a coordinated downregulation of MYC and IRF4 expression.
    Verdelli D; Nobili L; Todoerti K; Intini D; Cosenza M; Civallero M; Bertacchini J; Deliliers GL; Sacchi S; Lombardi L; Neri A
    Hematol Oncol; 2009 Mar; 27(1):23-30. PubMed ID: 18759374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
    van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
    Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide for the treatment of B-cell malignancies.
    Chanan-Khan AA; Cheson BD
    J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide mode of action: linking bench and clinical findings.
    Davies F; Baz R
    Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.
    Neuber B; Herth I; Tolliver C; Schoenland S; Hegenbart U; Hose D; Witzens-Harig M; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunol; 2011 Jul; 187(2):1047-56. PubMed ID: 21677134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM.
    Li S; Pal R; Monaghan SA; Schafer P; Ouyang H; Mapara M; Galson DL; Lentzsch S
    Blood; 2011 May; 117(19):5157-65. PubMed ID: 21389327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
    Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
    Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitation of multiple myeloma oncogene 1/interferon-regulatory factor 4 gene expression in malignant B-cell proliferations and normal leukocytes.
    Yamada M; Asanuma K; Kobayashi D; Moriai R; Yajima T; Yagihashi A; Yamamori S; Watanabe N
    Anticancer Res; 2001; 21(1B):633-8. PubMed ID: 11299818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
    De Matteo M; Brunetti AE; Maiorano E; Cafforio P; Dammacco F; Silvestris F
    Leuk Res; 2010 Feb; 34(2):243-9. PubMed ID: 19656567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion.
    Aldinucci D; Celegato M; Borghese C; Colombatti A; Carbone A
    Br J Haematol; 2011 Jan; 152(2):182-90. PubMed ID: 21114485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma.
    Armellini A; Sarasquete ME; García-Sanz R; Chillón MC; Balanzategui A; Alcoceba M; Fuertes M; López R; Hernández JM; Fernández-Calvo J; Sierra M; Megido M; Orfão A; Gutiérrez NC; González M; San Miguel JF
    Br J Haematol; 2008 Apr; 141(2):212-5. PubMed ID: 18353163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
    Greenberg AJ; Walters DK; Kumar SK; Rajkumar SV; Jelinek DF
    Eur J Haematol; 2013 Dec; 91(6):504-13. PubMed ID: 23992230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2.
    Zhu YX; Yin H; Bruins LA; Shi CX; Jedlowski P; Aziz M; Sereduk C; Kortuem KM; Schmidt JE; Champion M; Braggio E; Keith Stewart A
    Blood; 2015 Jan; 125(3):483-91. PubMed ID: 25395420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.